Phase 1 Myeloma Trial, Recruiting NCT06084962 Sponsor: He Huang Condition: Myeloma
Back to Myeloma

Phase 1 Myeloma Trial, Recruiting

NCT06084962
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and have given your written agreement to join the study
  • You are between 18 and 75 years old (any gender)
  • Your doctor estimates you are likely to live for at least 12 weeks
  • You are reasonably active and able to care for yourself, with limited or no restrictions on daily activities (confirm with trial site)
  • You have been diagnosed with multiple myeloma based on recognised international guidelines
  • You have already received at least 3 different types of treatment for multiple myeloma, including specific drug types (proteasome inhibitors, immunomodulatory agents, and a CD38 antibody), and your disease has come back or stopped responding to treatment
  • If you are a woman who could become pregnant, you have a negative pregnancy test before starting and agree to use effective birth control throughout the trial
  • Your blood test results meet minimum required levels for certain blood cells (confirm specific values with trial site)

Who may not be able to join:

  • You have a history of serious head injury, loss of consciousness, epilepsy/seizures, or bleeding or blockages in the brain
  • You have a history of serious heart conditions, including an abnormal heart rhythm or a specific irregular electrical signal in the heart (confirm with trial site)
  • You are currently pregnant or breastfeeding
  • You have HIV
  • You currently have an active hepatitis B or hepatitis C infection
  • You have been taking steroid tablets or injections (not inhalers) in the 2 weeks before joining the study
  • Your immune cells do not respond well enough to a specific laboratory test (confirm with trial site)
  • Your kidney or liver function blood tests are above certain levels (confirm specific values with trial site)
  • You have another cancer that is not under control, unless it was fully treated with no signs of disease in the past 3 years
  • You received a stem cell transplant using your own cells within 8 weeks before joining, or plan to have one during the study
  • You have ever received a stem cell transplant using someone else's cells
  • You received cancer treatment or certain other medications within 2 weeks before joining
  • The trial doctor believes there is any other reason that joining would not be safe or suitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: He Huang, MD, Zhejiang University

Phone: 86-13605714822

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
He Huang
Registry
ClinicalTrials.gov
Start date
20 October 2023
Est. completion
20 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-limiting toxicity (DLT); Incidence of treatment-emergent adverse events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov